Summary

The global biobanking market size was valued at USD 64.3 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 101.1 Billion by 2033, exhibiting a CAGR of 5.2% from 2025-2033. North America currently dominates the market, holding a market share of over 34% in 2024. The rising number of genomic research activities, increasing prevalence of chronic diseases, and rising focus on virtual biobank represent some of the key factors driving the market.

The global biobanking market is expanding due to increased demand for high-quality biological samples in medical research and personalized medicine. Advances in genomics and proteomics are driving the need for well-maintained biospecimens to support drug discovery, disease diagnosis, and biomarker development. For instance, in August 2024, Mayo Clinic's Center for Individualized Medicine launched an omics strategy, integrating genomics, proteomics, metabolomics, and microbiomics to explore gene-environment interactions. This initiative focuses on advancing disease prediction, diagnosis, and management, including cancer and chronic conditions. By utilizing polygenic risk scores and advanced sequencing, the center aims to deliver personalized healthcare and innovative treatment solutions. Government and private investments in biobanking infrastructure and the growing focus on regenerative medicine further boost the market. Additionally, the integration of advanced storage technologies, such as automated sample management systems, enhances efficiency and reliability, fueling market growth.

Rising awareness of the importance of biobanks in combating global health challenges, including cancer and rare diseases, is significantly influencing the market, especially in Europe. The adoption of digital platforms for data management and remote sample tracking ensures better accessibility and transparency. Moreover, collaborations between research institutions, pharmaceutical companies, and biobanks are accelerating innovations, reinforcing the market's role in supporting advancements in clinical research and therapeutics. For instance, in April 2024, EIT Health Scandinavia, part of the European Institute of Innovation and Technology (EIT), introduced the EIT Health Biobanks and Health Data Registries platform. This hub connects researchers, clinicians, and industry professionals with European biobanks and data registries. Developed with BBMRI-ERIC, it simplifies access, boosts sample utilisation, and fosters collaboration to drive medical research and innovation.

Biobanking Market Trends:
Expanding Role of Biobanking in Genomic Research and Personalized Medicine
At present, the rising demand for biobanking due to the increasing number of genomic research activities represents one of the key factors supporting the growth of the market. Besides this, the growing number of biobanks across the globe, due to its potential to enhance the reproductivity and meaning of data generated by biomedical research, is offering a positive market outlook. Additionally, there is a rise in the prevalence of chronic diseases, such as diabetes, hypertension, cancer, heart attack, and respiratory disorders, among the masses around the world. The World Health Organization (WHO) reports that chronic diseases account for 41 Million deaths annually, representing 74% of all global fatalities. This, coupled with the increasing demand for biobanking to develop diagnostics that can effectively identify pathogens, is propelling the growth of the market. Apart from this, the rising expenditure in advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, is offering lucrative growth opportunities to industry investors. For instance, the UK Biobank has collected genetic data from 500,000 participants, including whole genome sequencing (WGS) for all, whole exome sequencing (WES) for 470,000, and genotyping of 800,000 variants, with imputation extending this to 90 Million variants. Moreover, the increasing demand for biospecimens from clinical labs to develop assays for genetic testing is positively influencing the market. In addition, the growing focus on virtual biobank that minimizes time constraints, generates high revenue, and allows researchers to conduct the research smoothly is contributing to the growth of the market. Furthermore, key players are introducing a biobank software solution that assists in gaining visibility and improving the quality of the service provided to customers, which is strengthening the market growth.
Increasing Adoption of Digital Biobanking Solutions
The adoption of digital technologies is transforming the global biobanking market, improving efficiency, and ensuring better data management. Virtual biobanks are gaining traction for their ability to eliminate geographical and logistical barriers, providing researchers seamless access to biospecimens and associated data. Digital platforms enhance transparency, enable real-time tracking, and streamline operations, contributing to better sample integrity. For instance, in August 2024, Verisense Health, Inc. launched the Verisense Digital Biobank, with health data from over one million people, expected to reach two million by the end of 2024. It includes data from 570 studies and uses an AI-powered Dataset Cataloger to manage and update datasets. This helps researchers access, validate, and use digital health data more efficiently. Additionally, advancements in biobank management software are enabling stakeholders to optimize storage conditions, improve compliance, and increase operational scalability, ensuring high-quality biospecimens for research and diagnostics.
Expanding Demand for Biospecimens in Chronic Disease Research
The rising prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular conditions, is fueling demand for biospecimens to support diagnostics and therapeutic advancements. Biobanks play a vital role in developing innovative solutions for early detection and treatment by providing access to diverse biological samples. For instance, in November 2024, Oxford Nanopore Technologies partnered with UK Biobank to develop the first large-scale epigenetic dataset, sequencing 50,000 samples using advanced DNA/RNA technology. This initiative aims to uncover disease mechanisms, enhance diagnostics, and advance personalised treatments. By providing nearly complete epigenome insights, the project supports breakthroughs in healthcare, including early detection, tailored interventions, and improved understanding of disease progression. Moreover, with chronic diseases accounting for the majority of global fatalities, research institutions and pharmaceutical companies are leveraging biobanking to accelerate clinical trials and develop targeted therapies. Collectively, this trend underscores biobanking's importance in addressing global healthcare challenges and enhancing patient outcomes.

Biobanking Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global biobanking market, along with forecast at the global, regional, and country levels from 2025-2033. The market has been categorized based on specimen type, biobank type, application, and end-user.
Analysis by Specimen Type:
? Blood Products
? Solid Tissue
? Cell Lines
? Nucleic Acid
? Others
According to the report, blood products are the leading specimen type in the global biobanking market, owing to their pivotal role in advancing medical research, diagnostics, and therapeutic innovations. Comprising plasma, serum, and whole blood, these samples are integral to studying biomarkers, genetic disorders, and disease mechanisms. Their widespread application in research on chronic conditions such as cancer, cardiovascular diseases, and diabetes highlights their significance. Blood products are also essential for infectious disease studies, aiding in vaccine development and diagnostics. The integration of advanced storage and preservation technologies ensures the integrity and reliability of these specimens, supporting their use in longitudinal and cross-sectional studies. Furthermore, the growing emphasis on precision medicine and genomics has amplified the demand for blood samples, as they enable the development of personalized therapeutic solutions. The expanding global biobanking infrastructure, coupled with collaborations among research institutions and pharmaceutical companies, enhances the accessibility and quality of blood specimens. This strong demand solidifies blood products' position as the dominant specimen type in the global biobanking market, driving innovation and contributing to improved healthcare outcomes.
Analysis by Biobank Type:
? Population-based Biobanks
? Disease-oriented Biobanks
According to the report, disease-oriented biobanks dominate the global biobanking market as they provide critical resources for advancing research and treatments focused on specific diseases. These biobanks collect, store, and manage biological samples, such as tissues, blood, and DNA, specifically related to conditions like cancer, cardiovascular diseases, and neurological disorders. Their targeted approach supports precision medicine initiatives by enabling the identification of disease biomarkers, understanding disease mechanisms, and developing tailored therapies. The increasing prevalence of chronic and rare diseases worldwide has amplified the demand for disease-oriented biobanks, driving investments from governments, research institutions, and pharmaceutical companies. Advanced data integration and sample management technologies further enhance their value, enabling seamless sharing of high-quality biospecimens and associated data. These biobanks also play a pivotal role in supporting clinical trials and accelerating the development of innovative diagnostics and treatments. With their focused contribution to global healthcare challenges, disease-oriented biobanks are the cornerstone of modern biobanking, ensuring meaningful progress in disease management and therapeutic advancements.
Analysis by Application:
? Therapeutics
? Research
According to the report, research is the leading therapeutics segment in the global biobanking market, driven by the increasing need for high-quality biospecimens to support advancements in medical science and therapeutic innovation. Biobanks are uniquely positioned as the main infrastructures sourcing samples and data for research on diseases and drug discovery and as nuanced repositories of biomarkers to help advance treatment outcomes. Nevertheless, the biobanks with a research orientation have emerged with the growth in precision medicine and genomics because of the maximum importance of developing biomolecules for treatment from the patient’s genetic profile. Also, biobanks have the function of responding to the worldwide health problems by contributing to research on the chronic, infectious, and rare genetic diseases. Advancements in sample preservation and handling enhance the application of stored tissues a s useful tools of effective clinical trials and other applications. The relationship between biobanks, research institutions, and pharmaceutical companies enhance the ecosystem and overlays efficiency in discovery of treatments. This firm association with research activities places it as the largest therapeutics segment in the biobanking market, which is facilitating advancements in global healthcare.
Analysis by End-User:
? Academic Institutions
? Pharma and Biotech Companies
Pharma and biotech companies lead the market with around 58.3% of market share in 2024. Companies involved in pharma and biotech industries are highly motivated by the utilization of biospecimens in therapeutic products, trials, and precision medicine. These companies rely on biobanks to obtain high quality phenotype samples for biomarker identification, target validation as well as therapeutic validation. The inclusion of biobanking resources into the R&D value chains advances in the timeframe of the preclinical stage and increases productivity in drug development. Due to the trend towards the development of more and more chronic diseases and few occurrences of single diseases, there has been a growing need for various types of biological products, which can improve the methods of treatment for individuals and the technologies for tissue engineering and regeneration. Pharma and biotech firms also benefit from advanced biobank technologies, including automated storage systems and AI-driven data analytics, which enhance sample integrity and optimize utilization. Collaborations with biobanks provide these companies with access to ethically sourced specimens, ensuring compliance with regulatory standards and bolstering their research capabilities. By driving innovation and enabling groundbreaking therapies, pharma and biotech companies play a pivotal role in shaping the global biobanking market and advancing global healthcare solutions.
Regional Analysis:
? North America
o United States
o Canada
? Asia-Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Others
? Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Others
? Latin America
o Brazil
o Mexico
o Others
? Middle East and Africa
In 2024, North America accounted for the largest market share of over 34%. The North America region is driven by advanced healthcare infrastructure, significant investments in research and development, and a strong focus on precision medicine. The region benefits from robust biobank networks, supporting large-scale genomic and disease-specific research. Private sector initiatives in association with government funding are further improving the accessibility and quality of biospecimens, thereby forming strong stewardship. Moreover, North America is paying more attention to cutting-edge technologies adoption, including automated biobank management systems and AI-driven analytics. These technologies also improve sample preservation and data integration facilities that validates reliability for research applications. Increase in the incidences of chronic diseases such as cancer, and cardiovascular diseases put more emphasis on the procurement of good quality biospecimens for diagnostics and other therapeutic developments. This creates synergy among various institutions, research centers, and pharmaceutical industries with the result of promoting higher research outcomes of personalized medicine and regenerative options. North America, which continually exhibits a high level of commitment to legal requirements as well as ethics in biobanking, continues to lead in the growth of the worldwide business and its contributions to medical innovation.
Key Regional Takeaways:
United States Biobanking Market Analysis
The US accounted for 84.5% market share in North America. This can be attributed to the rising demand for personalized medicine, advancements in genomics, and increasing government investments in healthcare infrastructure. According to the U.S. Department of Health and Human Services, an estimated 129 Million Americans are affected by at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. This growing prevalence of chronic conditions has heightened the need for biobanks to support research in targeted therapies and precision medicine. Robust funding from institutions such as the National Institutes of Health (NIH) further accelerates biobank development, fostering advancements in genomics and biomedical research. Additionally, the integration of advanced technologies like artificial intelligence (AI) and machine learning enhances the analysis of complex datasets, significantly improving biobank capabilities. Collaboration among private biotech companies, academic institutions, and healthcare organizations strengthens the biobanking ecosystem. Regulatory frameworks, such as the Health Insurance Portability and Accountability Act (HIPAA), ensure secure management and sharing of biological data, instilling trust and encouraging participation. Together, these factors propel the growth of the U.S. biobanking market.
Asia Pacific Biobanking Market Analysis
The biobanking market in the Asia-Pacific (APAC) region is driven by advancements in healthcare infrastructure, increased government investment in research, and growing awareness of personalized medicine. According to the United Nations, China and India account for 18% of the world’s population, providing a diverse genetic pool for biobank development. Also, according to the NIH, the 3 major NCDs in the Asia Pacific region are CVDs, cancer and diabetes due to the increasing loss of disability adjusted life years (DALYs). These nations, alongside Japan, play a significant role in advancing genomics research, particularly in cancer and genetic disorders. Expanding healthcare initiatives in countries like India and South Korea, coupled with supportive government policies, further stimulate market growth. International collaborations with global biopharmaceutical companies strengthen biobank capabilities, fostering innovation and research across the region. The combination of population diversity and research focus positions APAC as a key player in the global biobanking landscape.
Europe Biobanking Market Analysis
The European biobanking market is witnessing significant growth, driven by government funding, advancements in biotechnology, and the increasing emphasis on personalized medicine. According to the European Commission, over 35% of the EU population reported a chronic health condition in 2023, including cardiovascular diseases, diabetes, and cancer. This prevalence highlights the need for biobanks to support research and develop targeted therapies for these widespread conditions. Europe’s strong healthcare infrastructure, coupled with its collaborative ecosystem of universities, research organizations, and private enterprises, provides a solid foundation for biobank development. Key initiatives, such as the EU’s Horizon 2020 programme, have been instrumental in funding large-scale biobank projects focusing on genomics and disease-specific research. The adoption of advanced technologies and analytics further enhances the capabilities of European biobanks in managing and analyzing biological samples. Additionally, the region’s stringent regulatory frameworks, including the General Data Protection Regulation (GDPR), ensure the ethical collection, storage, and use of biological data, fostering trust among stakeholders and encouraging public participation. These factors collectively position Europe as a global leader in biobanking, playing a crucial role in advancing medical research, supporting precision medicine, and addressing the growing healthcare challenges associated with chronic diseases.
Latin America Biobanking Market Analysis
The biobanking market in Latin America is driven by rising research investments and a growing focus on chronic disease management. According to the NIH, Brazil alone reported an estimated 928,000 deaths from chronic diseases, highlighting the need for enhanced medical research and biobank support. Governments in countries like Brazil and Mexico are strengthening healthcare infrastructure, creating opportunities for biobank development. Additionally, collaborations with international research institutions and private companies are improving biobank capabilities. While challenges like data management and regulatory frameworks persist, ongoing advancements in these areas are expected to drive further market growth in the region.
Middle East and Africa Biobanking Market Analysis
The Middle East and Africa biobanking market is gaining traction, driven by advancements in healthcare infrastructure and investments in cutting-edge technologies. In the UAE, the Al Jalila Foundation, part of the Mohammed Bin Rashid Al Maktoum Global Initiatives, invested USD 4.6 Million (AED 17 Million) to establish a state-of-the-art robotic biobank in 2022. Developed in collaboration with the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) and the Dubai Health Authority (DHA), the biobank will use advanced robotics and artificial intelligence to securely store over seven Million biological samples in cryogenic conditions below -80°C for genetic research. Such initiatives underscore the region's focus on leveraging technology to enhance research capabilities. Additionally, increasing government support and international collaborations further bolster the biobanking landscape in the region, paving the way for significant advancements in medical research and personalized medicine.
Competitive Landscape:
The global biobanking market is competitive, driven by advancements in technology, strategic collaborations, and the growing demand for high-quality biospecimens. Companies are focusing on developing innovative biobank management systems, automated storage solutions, and digital tools to enhance operational efficiency and meet research needs. Collaborative initiatives between biobanks, research organizations, and pharmaceutical firms are fostering innovation in genomic and personalized medicine. For instance, in August 2024, Owkin and Finnish Biobank Cooperative (FINBB) collaborated to advance medical research by applying AI to multimodal patient data. This partnership leverages 11 million biobank samples, biodata, and participant recruitment from Finland’s public biobanks. By combining expertise and resources, the initiative aims to accelerate innovative treatments for diseases like inflammatory bowel disease through impactful public-private partnerships. The rise of virtual biobanking and digital platforms is intensifying competition by improving accessibility and scalability. Market players are also emphasizing regulatory compliance, expanding biobank networks, and investing in R&D to address evolving healthcare challenges, further shaping the competitive landscape.
The report provides a comprehensive analysis of the competitive landscape in the keyword market with detailed profiles of all major companies, including:
? Brooks Automation Inc.
? Bay Biosciences LLC
? Boca Biolistics
? Ctibiotech
? Cureline Inc.
? Firalis
? Greiner Bio-One International GmbH
? Hamilton Company
? Merck KGaA
? ProteoGenex Inc.
? Thermo Fisher Scientific Inc.
? VWR Corporation (Avantor Inc.)

Key Questions Answered in This Report
1.What is Biobanking?
2.How big is the biobanking market?
3.What is the expected growth rate of the global biobanking market during 2025-2033?
4.What are the key factors driving the global biobanking market?
5.What is the leading segment of the global biobanking market based on the specimen type?
6.What is the leading segment of the global biobanking market based on the biobank type?
7.What is the leading segment of the global biobanking market based on the application?
8.What is the leading segment of the global biobanking market based on the end-user?
9.What are the key regions in the global biobanking market?
10.Who are the key players/companies in the global biobanking market?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Biobanking Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Specimen Type
6.1 Blood Products
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Solid Tissue
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Cell Lines
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Nucleic Acid
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Biobank Type
7.1 Population-based Biobanks
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Disease-oriented Biobanks
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Application
8.1 Therapeutics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Research
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by End User
9.1 Academic Institutions
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Pharma and Biotech Companies
9.2.1 Market Trends
9.2.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Brooks Automation Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.2 Bay Biosciences LLC
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.3 Boca Biolistics
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.4 Ctibiotech
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.5 Cureline Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Firalis
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.7 Greiner Bio-One International GmbH
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.8 Hamilton Company
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.9 Merck KGaA
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 ProteoGenex Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.11 Thermo Fisher Scientific Inc.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 VWR Corporation (Avantor Inc.)
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio

ページTOPに戻る

List of Tables/Graphs

List of Figures

Figure 1: Global: Biobanking Market: Major Drivers and Challenges
Figure 2: Global: Biobanking Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Biobanking Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Biobanking Market: Breakup by Specimen Type (in %), 2024
Figure 5: Global: Biobanking Market: Breakup by Biobank Type (in %), 2024
Figure 6: Global: Biobanking Market: Breakup by Application (in %), 2024
Figure 7: Global: Biobanking Market: Breakup by End User (in %), 2024
Figure 8: Global: Biobanking Market: Breakup by Region (in %), 2024
Figure 9: Global: Biobanking (Blood Products) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Biobanking (Blood Products) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Biobanking (Solid Tissue) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Biobanking (Solid Tissue) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Biobanking (Cell Lines) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Biobanking (Cell Lines) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Biobanking (Nucleic Acid) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Biobanking (Nucleic Acid) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Biobanking (Other Specimen Types) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Biobanking (Other Specimen Types) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Biobanking (Population-based Biobanks) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Biobanking (Population-based Biobanks) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Biobanking (Disease-oriented Biobanks) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Biobanking (Disease-oriented Biobanks) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Biobanking (Therapeutics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Biobanking (Therapeutics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Biobanking (Research) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Biobanking (Research) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Biobanking (Academic Institutions) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Biobanking (Academic Institutions) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: Biobanking (Pharma and Biotech Companies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: Biobanking (Pharma and Biotech Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: North America: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: North America: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: United States: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: United States: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Canada: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Canada: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Asia-Pacific: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Asia-Pacific: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: China: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: China: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Japan: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Japan: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: India: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: India: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: South Korea: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: South Korea: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: Australia: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: Australia: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Indonesia: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Indonesia: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: Others: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: Others: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: Europe: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: Europe: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: Germany: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: Germany: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: France: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: France: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: United Kingdom: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: United Kingdom: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Italy: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Italy: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Spain: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Spain: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Russia: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Russia: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Others: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Others: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Latin America: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Latin America: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Brazil: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Brazil: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Mexico: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: Mexico: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: Others: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: Others: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Middle East and Africa: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: Middle East and Africa: Biobanking Market: Breakup by Country (in %), 2024
Figure 79: Middle East and Africa: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 80: Global: Biobanking Industry: SWOT Analysis
Figure 81: Global: Biobanking Industry: Value Chain Analysis
Figure 82: Global: Biobanking Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Biobanking Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Biobanking Market Forecast: Breakup by Specimen Type (in Million USD), 2025-2033
Table 3: Global: Biobanking Market Forecast: Breakup by Biobank Type (in Million USD), 2025-2033
Table 4: Global: Biobanking Market Forecast: Breakup by Application (in Million USD), 2025-2033
Table 5: Global: Biobanking Market Forecast: Breakup by End User (in Million USD), 2025-2033
Table 6: Global: Biobanking Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Biobanking Market: Competitive Structure
Table 8: Global: Biobanking Market: Key Players